BUSINESS INSIGHTS
Medidata | April 01, 2022
A Dassault Systèmes company, Medidata, announced that Labcorp, a leading global life sciences company, has extended its 14-year partnership with Medidata, laying the groundwork for their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials.
“Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentralized clinical trial offerings. Our work to advance sensor and digital biomarker usage in clinical research can help accelerate patient care while providing valuable information to study sponsors.”
Bill Hanlon, Ph.D., chief scientific officer and president of Clinical Therapeutic and Regulatory Sciences, Labcorp Drug Development
Labcorp Drug Development's products are based on Medidata technology, including Rave EDC, Coder, and TSDV. In addition, Labcorp is currently using most of the Medidata Clinical Cloud platform, including eCOA, RTSM, and Imaging.
“The last two years have required clinical trials to become more accessible and flexible; these changes make our strategic partnership with Labcorp Drug Development to modernize and decentralize trials even more critical,” said Anthony Costello, CEO Patient Cloud at Medidata. “With this new agreement, we’re excited to develop and deploy the innovations that help our customers run more effective clinical programs and get new treatments to patients faster than ever before.”
Through its 3DEXPERIENCE platform, Medidata is positioned to lead the digital transformation of life sciences in the era of personalized medicine by providing the industry's first end-to-end scientific and business platform, from research to commercialization.
Read More
PHARMA TECH
AstraZeneca | November 13, 2020
Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in two tests in hospitalized patients. AstraZeneca said Thursday that the medicine—already approved in mantle cell lymphoma—didn't help patients survive the virus and reduce respiratory failure any better than supportive care did, citing data from two phase 2 trials. The company set out to test the medicine back in April after researchers at the NIH’s National Cancer Institute observed “some clinical benefit” when the drug was used in a small number of hospitalized COVID-19 patients with advanced lung disease at the Walter Reed Army Medical Center, Forbes reported at the time.
Read More
RESEARCH
IDBS | December 07, 2020
IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research.
The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that without compelling BPLM, the advancement of a biologic can take as long as three years longer than it should, which impacts the two patients and an organization's primary concern. Despite the fact that biopharma organizations perceive the requirement for proficiency, quality and information honesty, most are as yet losing time to paper records, Excel and other specially appointed frameworks that defer results and endanger measure understanding and quality. Without more productive frameworks, organizations will keep on creating irreproducible outcomes, which prompts rehashed work, inability to separate experiences and postpones development.
"Putting up a medication for sale to the public is an unpredictable cycle which proceeds with post-commercialization," said Umay Saplakoglu, Chief Digital Officer at Cytiva. "A significant test today is that information that is created all through the periods of disclosure doesn't generally get moved and rather exists in storehouses – in hardware, in somebody's scratch pad or in an information base. There are no communitarian stages where you can dissect the information and draw experiences from it. This remaining parts probably the greatest test confronting industry today."
Polar™ is intended to be quickly sent to explain work process, measure quality, joint effort and information investigation challenges that have pained presently accessible programming arrangements including LIMS and ELN. It will decrease manual information preparing and record, prompting less human mistakes and improved generally speaking precision, and incorporates complete pursuit capacities that help clients find what they are searching for, diminishing the need to pointlessly copy measures. Besides, by making a profoundly contextualized information spine that underpins the entire improvement lifecycle, Polar™ offers out-of-the-crate understanding and investigation, assisting organizations with understanding the advantages of demonstrating and reproduction, helping drive development and decrease time-to-showcase.
Polar™, will empower organizations to all the more viably explore the complexities and failures of the medication advancement lifecycle, while receiving the groundbreaking rewards that come from a well curated cycle and quality information spine.
Read More